Deans' stroke musings: Anti-Diabetic Drugs May Boost Stroke Recovery Outcomes

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, March 2, 2024

Anti-Diabetic Drugs May Boost Stroke Recovery Outcomes

Will your competent? doctor and hospital ensure human research gets initiated? NO? Then you don't have a functioning stroke doctor or hospital, you have dinosaurs.

Anti-Diabetic Drugs May Boost Stroke Recovery Outcomes

People with type 2 diabetes have an increased risk of stroke and a worsened outcome after suffering from it. Now, researchers at the Karolinska Institutet have shown that stroke outcome is significantly improved in mice with obesity and type 2 diabetes who have been treated with the commonly used diabetic drugs SGLT-2 inhibitors. The results are published in the scientific journal Cardiovascular Diabetology and may have clinical relevance for stroke rehabilitation in type 2 diabetes.

The number of people with diabetes in the world is expected to rise dramatically to 700 million in 2045. Stroke is one of the major complications in people with diabetes who also have a worsened prognosis in the rehabilitation phase. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a class of oral medications that lower blood sugar in adults with type 2 diabetes. These treatments have also been shown to reduce cardiovascular risk but if they improve the outcome after stroke is unknown.

Researchers at Karolinska Institutet show that if SGLT-2 inhibitors are given after stroke in diabetic mice, their functional recovery is greatly improved.

Ellen Vercalsteren, Postdoctoral Researcher

-This suggests that diabetic people suffering from stroke could improve their negative prognosis if treated with SGLT-2 inhibitors, says Ellen Vercalsteren, Postdoctoral Researcher at the Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet (KI SÖS) and first author of the study.

The researchers now plan to go ahead and study the potential association between different diabetic treatments and stroke outcome in clinical registry studies.

The study has been conceived by Vladimer Darsalia and Cesare Patrone at The NeuroCardioMetabol Group, Department of Clinical Science and Education, Södersjukhuset and is the result of a collaborative effort with the Translational Neurology Group, Department of Clinical Science, Wallenberg Neuroscience Center at Lund University, Boehringer Ingelheim Pharma GmbH & Co. KG and the Internal Medicine Unit at Södersjukhuset.

Funders of the study were Hjärnfonden, Ulla Hamberg Angeby och Lennart Angebys Stiftelse, the Swedish Research Council, STROKE-Riksförbundet, ALF and the Swedish Heart-Lung foundation.

Publication

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice, Ellen Vercalsteren, Dimitra Karampatsi, Carolina Buizza, Thomas Nyström, Thomas Klein, Gesine Paul, Cesare Patrone & Vladimer Darsalia, Cardiovascular Diabetology, online 29 Feb 2024, doi: 10.1186/s12933-024-02174-6

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.